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Abstract: Research towards the non-invasive imaging of atherosclerotic plaques is of high 
clinical priority as early recognition of vulnerable plaques may reduce the incidence of 
cardiovascular events. The fibroblast activation protein alpha (FAP) was recently proposed 
as inflammation-induced protease involved in the process of plaque vulnerability. In this 
study, FAP mRNA and protein levels were investigated by quantitative polymerase chain 
reaction and immunohistochemistry, respectively, in human endarterectomized carotid 
plaques. A published boronic-acid based FAP inhibitor, MIP-1232, was synthetized and 
radiolabeled with iodine-125. The potential of this radiotracer to image plaques was 
evaluated by in vitro autoradiography with human carotid plaques and FAP-positive 
melanoma xenograft tissue. Target expression analyses revealed a moderately higher 
protein level in atherosclerotic plaques than normal arteries correlating with plaque 
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vulnerability. No difference in expression was determined on mRNA level. The radiotracer 
was successfully produced and accumulated strongly in a FAP-positive melanoma 
xenograft in vitro. Binding of the tracer to endarterectomized tissue was similar in plaques 
and normal arteries, hampering its use for atherosclerosis imaging. Though this tracer 
might be of interest for tumor imaging and deserves further investigations. 
Keywords: Atherosclerosis; Fibroblast activation protein; carotid artery plaque; boronic 
acid-based inhibitor 
 
1. Introduction 
The concept of plaque vulnerability has changed the understanding of the pathogenesis of 
atherosclerosis and has led to novel perspectives for diagnostic and therapeutic interventions. 
Nowadays, plaque progression is regarded as a dynamic and complex process with stabilizing and 
destabilizing components involved. If destabilizing plaque components prevail over stabilizing factors 
an atherosclerotic plaque may eventually rupture leading to often severe or even fatal complications. 
Stabilizing components include an intact and thick fibrous cap that is formed by smooth muscle cells 
(SMCs) embedded in an extracellular matrix rich in collagen. On the contrary, plaque vulnerability is 
related to a thinning of the fibrous cap facilitated by the gradual loss of SMCs and the degradation of 
the collagen-rich fibrous cap [1]. The digestion of the extracellular matrix is caused by proteases in the 
atheromata which include matrix metalloproteinases (MMPs), cathepsins S/K and as recently proposed 
the fibroblast activation protein alpha (FAP, seprase) [2-5]. FAP is a type II membrane-bound serine 
protease belonging to the subfamily dipeptidyl peptidase IV N-terminal (DPP IV, S9B) within the 
prolyl oligopeptidase family (POP, S9) [6-8]. In contrast to other members of the DPP IV subfamily, 
FAP displays endo- besides exopeptidase activity [9]. FAP is capable of cleaving peptide bonds 
between proline and another amino acid which is glycine in its function as endopeptidase [9]. Besides 
its dipeptidyl peptidase activity, FAP has gelatinase activity and is involved in the further digestion of 
degradation products of type I collagen [10-13]. The endo- and exopeptidase enzymatic activity 
requires homodimerization and glycosylation of the protease [7,11,14]. 
FAP was initially identified as a pivotal component of the tumor microenvironment expressed by 
reactive stromal fibroblasts in over 90% of common human epithelial carcinomas [15-17]. 
Furthermore, an association of FAP expression with inflammatory processes was described [15] and in 
line with this finding is emerging data by Brokopp et al. indicating an involvement of FAP in the 
pathogenesis of atherosclerosis [4]. They showed that FAP is expressed by SMCs in human aortic 
plaques and confirmed its involvement in type I collagen degradation in aortic fibrous caps. Moreover, 
an association between tumor necrosis factor alpha (TNFα) secretion by macrophages with FAP 
expression in cultured human aortic SMCs and additionally a positive correlation of FAP-expressing 
SMCs with the macrophage burden in human aortic plaques was described. The extent of FAP 
expression at different stages in atherosclerotic plaque progression was evaluated and revealed an 
increased FAP expression in advanced aortic plaques and in thin-cap versus thick-cap coronary 
atheromata by immunohistochemistry and immunofluorescence [4]. These findings indicate that FAP 
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expression is related to plaque vulnerability with FAP representing an inflammation-induced protease 
in atherosclerosis. 
In this respect, FAP could serve as a promising target for non-invasive atherosclerotic plaque 
imaging. The development of diagnostic methods to assess plaque vulnerability is considered an urgent 
priority in clinical and basic research [18]. The assessment of plaque vulnerability in patients at risk for 
cardiovascular disease would allow an adequate pharmacological and/or surgical treatment already in 
the asymptomatic stage and, therefore, reduce atherosclerosis-associated disability and mortality. 
Molecular imaging with suitable tracers has the potential to non-invasively identify molecular 
processes providing functional information about disease progression. In the asymptomatic stage, 
functional imaging may thus provide more specific information on plaque vulnerability than 
morphology-based imaging modalities [19]. Several imaging targets and the respective tracers are 
under investigation with the goal to image plaque vulnerability. The most prominent tracer is 
[18F]fluordeoxyglucose, which accumulates in cells with high glucose consumption, including 
activated macrophages. However, the unspecific mechanisms of accumulation and the high uptake in 
myocardium limit its applicability [20]. We recently evaluated more specific markers of inflammation 
towards the imaging of vulnerable plaques. We confirmed increased levels of the gelatinase B MMP-9 
in vulnerable plaques but unfortunately, no ligand is available to target this protease selectively [5]. 
We furthermore identified the co-stimulatory molecule CD80 as a promising imaging target. It is 
involved in T-cell activation and its expression is increased in vulnerable plaques. A radiolabeled 
specific inhibitor accumulated in human vulnerable plaques in vitro [21]. Moreover, an F-18 labeled 
folate derivative targeting activated macrophages accumulated stronger in atherosclerotic plaques than 
normal arteries [22]. In agreement with other studies [23-25], our recent findings suggest that 
inflammation-related processes provide promising targets for the non-invasive imaging of plaque 
vulnerability. 
The goal of this study was to evaluate FAP as a target for atherosclerosis imaging. Imaging FAP 
density requires a FAP-selective ligand with high binding affinity. Several research groups have 
pursued to design small inhibitors with high specificity and selectivity towards individual serine 
proteases in the POP family. To selectively target FAP over other peptidases, its dual enzymatic 
activity as endo- and exopeptidase has to be considered. Identifying inhibitors with high selectivity for 
FAP over other DPPs and the most closely related endopeptidase prolyl endopeptidase (PREP) is 
challenging due to the 48% amino acid sequence identity of FAP and DPP-4, analogous substrate 
preferences and the ubiquitous expression of many proteases of the POP family [6,8]. Most FAP 
inhibitors share the pyrrolidine-2-boronic acid moiety as a common structural motif. The first boronic 
acid inhibitor reaching phase II clinical trials in the field of cancer treatment was ValboroPro 
(talabostat, PT-100), however due to missing selectivity clinical evaluation was terminated [26-28].  
ValboroPro displayed IC50 values in the nanomolar range to several prolyl peptidases [29]. 
Modifications in the dipeptidyl boronic acid structure with the introduction of a blocked N terminus 
led to novel inhibitors that were evaluated regarding binding affinity and selectivity [30-34]. The 
blocked N terminus in these molecules hampers intra-molecular cyclization reactions of the 
electrophilic boron being a common adverse inactivation mechanism of dipeptidyl boronic acid 
structures with a free amine at the N terminus [35]. Furthermore, a blocked N terminus increases 
selectivity over DPPs that lack endopeptidase activity. 
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Marquis et al. presented a para-iodine substituted benzamido-glycine-boronoproline analog, MIP-
1232, with an IC50 of 0.6 nM as determined in an enzyme inhibition assay with human recombinant 
FAP [34]. MIP-1232 was 32-fold more potent in inhibiting FAP than PREP. The corresponding Kd 
value of [123I]MIP-1232 in stably FAP-transfected human embryonic kidney cells (HEK-293) was 30 
nM and different FAP-positive cell lines showed a markedly reduced enzyme activity under MIP-1232 
treatment compared to baseline conditions [34,36]. The high binding affinity to FAP and the selectivity 
profile in combination with the possibility to radioiodinate MIP-1232 make this compound a 
promising molecule to assess the potential of FAP as an imaging target for the staging of plaque 
vulnerability and to detect FAP-positive tumors.  
In this study, we investigated FAP expression in human carotid specimens by quantitative 
polymerase chain reaction (qPCR) and immunohistochemistry (IHC). Furthermore, we synthesized 
MIP-1232 and subsequently radiolabeled this compound with iodine-125. Its accumulation in human 
atherosclerotic plaques and a FAP-positive melanoma xenograft was evaluated in vitro by 
autoradiography. 
 
2. Results 
2.1 Gene expression analysis of FAP and SMA in human carotid plaques 
Quantitative expression analysis of FAP and alpha smooth muscle cell actin (SMA) by qPCR was 
performed with β-actin as reference gene (Fig. 1). For FAP, a higher average gene expression was 
determined in plaques than normal arteries with stable plaques displaying the highest FAP levels (Fig. 
1A). Average SMA gene expression was highest in normal arteries with the lowest values in 
vulnerable plaques (Fig. 1B). Intergroup differences for FAP and SMA were not significant. No 
significant correlation between the SMA and FAP gene expression in human endarterectomized 
plaques was observed (Fig. 1C). 
 
Figure 1. Relative mRNA expression levels of FAP (A) and SMA (B) in normal arteries (n 
= 2), stable plaques (n = 11) and vulnerable plaques (n = 9). Differences were not 
significant. (C) Correlation of the relative mRNA expression levels of FAP and SMA. 
mRNA expression was quantified by qPCR, shown are averages of three independent 
analyses. Lines indicate mean value.  
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2.2 Immunohistochemical staining of human carotid plaques for FAP and SMA 
The expression of FAP and SMA was further investigated by immunohistochemistry in consecutive 
sections of human atherosclerotic plaques (Fig. 2). FAP staining intensity was weak in all examined 
endarterectomized tissues. Normal arteries were FAP negative. In plaques, a focal FAP expression in 
macrophages and giant cells located in the superficial regions of the fibrous cap was observed with the 
most pronounced focal signals in vulnerable plaques. SMA was strongly expressed in the tunica media 
in all three classification categories with the highest expression in the vasa vasorum of normal arteries 
(Fig. 2A, high magnification image). The distribution pattern of SMA within atherosclerotic plaques 
was generally focal with major clusters in the cap or shoulder region. No distinct co-localization of the 
two expression markers was found in all examined carotid plaques (Fig. 2B, high magnification 
images 1 and 2).  
Figure 2. Hematoxylin/eosin (HE) and immunohistochemical staining for FAP and SMA 
of representative sections of a normal artery (A), a stable plaque (B) and a vulnerable 
plaque (C). Boxed higher-magnification images show a small blood vessel (normal artery) 
and regions in the fibrous cap (stable and vulnerable plaque). The endarterectomized 
plaques are composed of tunica intima and part of the media. Scale bar, low magnification 
2000 µm and high magnification 200 µm. 
 
2.3 Chemistry and radiochemistry 
Reference compound and precursor were synthesized from commercially available 4-iodobenzoic 
acid and glycin ethylester hydrochloride, as shown in Fig. 3. The synthetic scheme followed that 
reported by Zimmerman et al. [36] with distinct modifications. For the reference compound, glycin 
ethylester was efficently coupled to 4-iodobenzoic acid with HBTU as the coupling agent to afford 
compound 1 in 79% yield. The ethylester was then cleaved under basic conditions (aq. KOH/MeOH) 
to give the free acid 2 in moderate yield (55%) [37]. Reaction of compound (2) with (R)-boroPro-(+)-
pinanediol-HCl using the EDC/HOBt coupling system afforded dipeptide 3 in excellent yield (93%). 
Deprotection of the boronic ester to the free boronic acid, proved challenging. The proposed 
transesterfication method [36] with phenylboronic acid was not efficient in our hands. Apart from 
solubility problems the reaction was sluggish producing many byproducts. Thus, an alternative method 
was applied, which involved oxidative cleavage of the pinanediol moiety using sodium metaperiodate 
[38]. This procedure was more compatible with our substrate, yielding cleanly and relatively fast a new 
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more polar product as revealed by HPLC monitoring. After workup, the crude was purified with 
preparative RP-HPLC to provide 4 in moderate yield (45%). 
 
For the synthesis of the precursor, a similar procedure was followed. Stannylation of the iodinated 
compound 2 was achieved by reacting it with hexamethylditin and Pd(PPh3)2Cl2 in refluxing dioxane, 
which yielded compound 5 in a good yield (81%). 5 was then coupled to the boronic ester (R)-
boroPro-(+)-pinanediol with EDC/HOBt in DCM and the crude was purified with RP-HPLC to 
provide the precursor 6 in satisfactory yield (59%). 
 
Figure 3. Synthesis of reference compound 4 and corresponding precursor 6. Reagents and 
conditions: (a) HBTU, DIPEA, DMF, rt, 3 h, 79%; (b) KOH, MeOH/H2O, rt, 1 h, 55%; (c) 
EDC, HOBt, (R)-BoroPro-(+)-Pinanediol-HCl, DCM, 0 °C to rt, 16 h, 93%;(d) NH4OAc, 
NaIO4, acetone, rt, 17 h, 45%; (e) hexamethylditin, Pd(PPh3)2Cl2, dioxane, rt, 3 h, 81%; (f) 
EDC, HOBt, (R)-BoroPro-(+)-Pinanediol-HCl, DCM, 0 °C to rt, 16 h, 59%. 
 
 
[125I]MIP-1232 was produced in a one-step reaction by electrophilic radioiodination of the 
corresponding trimethylstannyl precursor (Fig. 4). The procedure was performed according to 
Zimmerman et al. [36] with some modifications since the order of addition of the reagents critically 
affected the outcome of the reaction. The experimental protocol was optimized so as to yield a reliable 
and robust radiolabeling procedure. Briefly, precursor 6 was incubated with Na[125I] under oxidative 
conditions to achieve electrophilic radioiodination which led simultaneously to cleavage of the boronic 
acid protecting group. After quenching with Na2S2O3, the reaction mixture was purified by analytical 
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HPLC to yield [125I]MIP-1232 in 10 – 12 % radiochemical yield (decay-corrected; n = 3) and 
radiochemical purity ≥ 90%.  
 
Figure 4. Radioiodination scheme of precursor 6 to [125I]MIP-1232. Reagents and 
conditions: Na[125I], H2O2, H2SO4, CH3COOH, MeCN, rt, 10 min then Na2S2O3.  
	  
 
2.4 In vitro autoradiography 
Radiotracer binding was evaluated by in vitro autoradiography with human carotid plaques and 
xenograft tissue, as shown in Fig. 5. [125I]MIP-1232 binding was higher in atherosclerotic plaques than 
normal arteries. Vulnerable plaques showed a slightly higher radioactivity signal than stable plaques. 
However, after correction for the size of the tissue samples, average total binding was similar for the 
three categories (Fig. 5A and B). Radiotracer binding was reduced under blockade conditions with an 
excess of unlabeled MIP-1232 indicating specific binding of [125I]MIP-1232 (Fig. 5A). The quantified 
average specific binding was higher in plaques than normal arteries, however, with no significant 
difference between stable and vulnerable plaques and between plaques and normal arteries, 
respectively (Fig. 5B). Furthermore, target specificity of [125I]MIP-1232 was evaluated in an 
autoradiography assay with xenograft tissue (Fig. 5C). FAP-positive Sk-Mel-187 melanoma xenografts 
displayed a markedly higher radioactivity signal than FAP-negative NCI-H69 lung small cell 
carcinoma xenografts and radiotracer binding was blocked completely by excess of MIP-1232 in both 
xenografts. 
 
Figure 5. (A) In vitro autoradiogram of representative sections of human carotid plaques 
under baseline ([125I]MIP-1232) and blockade condition ([125I]MIP-1232 with excess 
unlabeled MIP-1232). Hematoxylin/eosin (HE) staining below represents plaque 
morphology. Scale bar 3 mm. (B) Quantified total and specific binding of [125I]MIP-1232 
to normal arteries (n = 5), stable plaques (n = 16) and vulnerable plaques (n = 15) 
determined by autoradiography and corrected for tissue size. No significant intergroup 
differences were determined. Lines indicate mean values, diamonds indicate the specimens 
shown in A. (C) In vitro autoradiography with xenografts under baseline and blockade 
conditions. Scale bar 3 mm. Color scales for minimal to maximal binding. 
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3. Discussion 
In a recent study, Brokopp et al. examined the levels and localization of FAP in coronary and aortic 
plaques reporting an increased level in advanced plaques indicating an association of FAP with the 
process of plaque destabilization [4]. Our plaque specimens, obtained from the carotid artery, showed 
similar FAP mRNA levels as normal artery segments, independent of plaque vulnerability. In 
agreement with Brokopp et al., FAP protein levels as determined by IHC correlated with plaque 
progression, with the highest focal staining in vulnerable plaques. The discrepancy between mRNA 
and protein levels could indicate lower degradation of FAP in vulnerable than stable plaques, in line 
with differences in protease and protease inhibitor levels in the two lesion types [5]. Overall, the 
difference in FAP expression between normal arteries and plaques was modest in our study. In contrast 
to the publication of Brokopp et al., we found FAP protein in macrophages and giant cells within the 
plaque and found no co-localization with SMCs. However, we want to point out that Brokopp et al. 
evaluated artery segments of a different location. 
By qPCR, a lower SMA expression was detected in atherosclerotic plaques than normal arteries. 
This reflects the lower relative contribution of tunica media, consisting mainly of SMCs, to total tissue 
mass in atherosclerotic than normal artery. The higher SMA mRNA level in stable than vulnerable 
plaques is possibly a consequence of the thinning of the fibrous cap and the concurrent loss of SMCs 
in highly inflamed plaques. SMA immunohistochemistry showed an equal distribution pattern limited 
to muscular parts in all three classification categories with the most prominent signals in the tunica 
media and in the vasa vasorum. Faint focal staining signals were in addition detected in the 
atherosclerotic plaques.  
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The FAP inhibitor MIP-1232 was successfully synthesized and radiolabeled with iodine-125, a 
long-lived gamma-emitting nuclide. The synthesis and radiolabeling were accomplished in reasonable 
yields and purity. In a proof-of-principle study with a FAP-positive Sk-Mel-187 xenograft [39], a high 
and specific binding of the radiotracer was observed, whereas binding to a FAP-negative xenograft 
was negligible. This indicates binding of [125I]MIP-1232 to FAP-positive tissue in vitro. The potential 
of this radiotracer for atherosclerotic plaque imaging was investigated by in vitro autoradiography with 
human carotid plaques. Here, we found a pronounced binding to carotid plaques, however with no 
difference in average specific binding between stable and vulnerable plaques and between plaques and 
normal arteries, after correction for the size of the tissue samples. However, 3 of the 16 stable and 4 of 
the 15 vulnerable plaques showed several-fold higher specific accumulation than normal arteries. Only 
a prospective study would show whether this correlates with any clinical outcome. 
Based on our data we cannot conclude on the selectivity of [125I]MIP-1232 for FAP. In the absence 
of a known selective inhibitor, we investigated specificity by blocking with the unlabeled compound 
itself. The relatively high amount of remaining tracer after blocking must, therefore, accumulate with 
low affinity. Lipophilicity is most probably not involved as ClogP of MIP-1232 is about 0.5. The non-
specific accumulation may result from interactions with highly abundant hydrolases or other proteins 
with affinities in the high micromolar range, considering that our blocker concentration was 100 µM. 
Specificity analysis of MIP-1232 was performed exclusively with FAP and PREP [34]. A conclusive 
evaluation of the binding affinity to dipeptidyl peptidases and possibly other proteases would be 
required, irrespective of the fact that DPPs display in general low affinities for N blocked peptides [40]. 
To overcome limitations in specificity, novel lead structures and the use of antibodies and fusion 
proteins was proposed to minimize off-target effects [29,39,41].  
The mechanistic role of FAP in atherosclerosis remains vague. Collagen, thereof 70% collagen type 
I, is a primary component of the extracellular matrix in atherosclerotic plaques and is an important 
component of plaque stabilization [42]. Synergistically with matrix metalloproteinases, FAP is capable 
of degrading type I collagen and these proteases therefore have a destabilizing effect on atherosclerotic 
plaques [12]. Lately, an association was proposed of a single nucleotide polymorphism of the DPP-4 
gene and increased occurrence of myocardial infarction in patients with coronary artery disease [43]. 
Carriers of the polymorphic allele displayed reduced DPP-4 plasma levels. The involvement of serine 
proteases, in particular of the DPP IV subfamily, in atherosclerosis and its clinical adverse events 
certainly warrants further investigations. 
In this study we found moderately elevated FAP in atherosclerotic plaques with similar levels in 
stable and vulnerable plaques, which questions the use of FAP inhibitors for imaging plaque 
vulnerability. However, the high and specific in vitro accumulation of [125I]MIP-1232 in the melanoma 
xenograft looks promising regarding FAP as an imaging target in oncology. Our center is currently 
evaluating radiolabeled FAP inhibitors in xenograft models. 
 
4. Experimental Section  
4.1 Patient characteristics and human carotid tissue banking 
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Human atherosclerotic plaque tissues were excised during carotid endarterectomy (CEA) surgery at 
the University Hospital Zurich using the bifurcation advancement technique [44]. The atherosclerotic 
material was removed from the common, external and internal carotid artery. Before surgery, written 
informed consent was obtained from all patients. A total of 25 patients were included in this study with 
an average age of 73.1 years (73.1 ± 6.6 y) at surgery and 84% of them male. After CEA, the tissue 
was transferred to RNAlater® solution (Sigma, St. Louis, USA) and stored at -80°C until further use. 
Excised material was classified into the categories “normal artery”, “stable plaque” and “vulnerable 
plaque” based on a macroscopic visual inspection and a histological examination. The histological 
analysis was performed with standard staining methods (e.g. hematoxylin and eosin) and according to 
the classification system of the American Heart Association as previously described [21,45]. Plaques 
were classified as stable if there was a lipid core separated to the blood stream by an intact fibrous cap 
with a representative cap thickness >500 µm and a minimum cap thickness >200 µm [46]. Vulnerable 
plaques were lesions with a large necrotic core, a thin or ruptured fibrous cap, high infiltration of 
inflammatory cells and neovascularization. The microscopic characterization of all plaques used in this 
study was in agreement with the macroscopic evaluation. In total 7 normal arteries, 25 stable plaques 
and 23 vulnerable plaques were used for gene expression analysis, immunohistochemistry and 
autoradiography, respectively. Classified normal arteries were redundant segments from the A. iliaca 
or A. thyroidea. 
 
4.2 RNA isolation, Reverse-Transcription and Real-Time Polymerase Chain Reaction 
Total RNA was isolated from human atherosclerotic plaque segments according to the protocol of 
the Isol-RNA Lysis reagent (5 PRIME, Gaithersburg, USA) using the bead-mill TissueLyser system 
(Qiagen, Hilden, Germany). cDNA was generated by the QuantiTect Reverse Transcription Kit 
(Qiagen, Hilden, Germany). Used primers were custom-made oligonucleotides from Microsynth 
(Balgach, Switzerland): human actin beta (ACTB) (forward 5’-CATGTACGTTGCTATCCAGGC-3’, 
reverse 5’-CTCCTTAATGTCACGCACGAT-3’, NM_001101), human fibroblast activation protein 
alpha (FAP) (forward 5’- TGAACGAGTATGTTTGCAGTGG-3’, reverse 5’- 
GGTCTTTGGACAATCCCATGT-3’, NM_004460) and human alpha smooth muscle cell actin 
(SMA) (forward 5’- GCTGGCATCCATGAAACCAC-3’, reverse 5’- 
TGCCCCCTGATAGGACATTG-3’, NM_001613). Quantitative polymerase chain reaction (qPCR) 
was performed with the DyNAmoTM Flash SYBR® Green PCR System (Applied Biosystems, 
Carlsbad, USA) using a AB7900 HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, 
USA). Quantification was performed by the 2-∆∆Ct quantification method with β-actin as a reference 
gene [47]. All reactions were conducted in duplicates in three independent experiments. Specificity of 
the amplification products was assured by dissociation analysis. SMA is specifically expressed in 
SMCs of different origin. 
 
4.3 Histology and immunohistochemistry 
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Plaques were paraffin-embedded and serial sections of 2 µm were prepared for further histological 
and immunohistochemical investigations. Hematoxylin and eosin (HE) staining was performed 
according to routine procedure to classify plaques into the categories “stable” and “vulnerable”. For 
immunohistochemistry, primary antibodies for FAP (anti-FAP, 1:50, rabbit, polyclonal antibody 
directed against the Fibroblast activation protein, N3100-91763, Novus Biologicals, Littleton, CO, 
USA) and SMA (anti-SMA, 1:400, mouse, monoclonal antibody directed against anti-human alpha 
smooth muscle actin, M0851, Dako, Baar, ZG, Switzerland) were used. Antigen retrieval for the anti-
FAP antibody was performed using acid buffer (pH 6.0), whereas no antigen retrieval was performed 
for the anti-SMA antibody. The detection system included the OmniUltraMab Kit (Roche, Rotkreuz, 
ZG, Switzerland) for the anti-FAB antibody on the Discovery XT instrument (Roche) and the Dako 
RealKit (Dako) for the anti-SMA antibody on the immunostainer (Dako). Sections were scanned by a 
slide scanner (Pannoramic 250, 3D Histech, Sysmex, Horgen, Switzerland).   
 
4.4 Chemicals and reagents 
All reagents and starting materials were purchased from commercial suppliers and used without 
further purification. All solvents used for reactions were obtained as anhydrous grade from Acros 
Organics (puriss., dried over molecular sieves, H2O <0.005%) and were used without further 
purification unless otherwise stated. Solvents for extractions, column chromatography and thin layer 
chromatography (TLC) were purchased as commercial grade. All non-aqueous reactions were 
performed under an argon atmosphere using flame-dried glassware and standard syringe/septa 
techniques. In general, reactions were magnetically stirred and monitored by TLC performed on Merck 
TLC glass sheets (silica gel 60 F254). Spots were visualized with UV light (λ = 254 nm) or through 
staining with anisaldehyde solution or basic aq. KMnO4 solution and subsequent heating. 
Chromatographic purification of products was performed using Fluka silica gel 60 for preparative 
column chromatography (particle size 40 – 63 µm). Reactions at 0 °C were carried out in an ice/water 
bath. Nuclear magnetic resonance (NMR) spectra were recorded in CDCl3, CD3OD or DMSO-d6 on a 
Bruker Av-400 spectrometer at room temperature. The measured chemical shifts are reported in δ 
(ppm) and the residual signal of the solvent was used as the internal standard (CDCl3 1H: δ = 7.26 
ppm, 13C: δ = 77.0 ppm; CD3OD: 1H: δ = 3.31 ppm, 13C: δ = 49.15 ppm; DMSO-d6 1H: δ = 2.50 ppm, 
13C: δ = 39.51 ppm). All 13C NMR spectra were measured with complete proton decoupling. Data of 
NMR spectra are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd 
= doublet of doublets, dt = doublet of triplets, br = broad signal. The coupling constant J is reported in 
Hertz (Hz). Electrospray (ES) mass spectra (HRMS) were obtained with a Bruker's maXis (ESI-Qq-
TOF-MS) spectrometer. Analytical HPLC was performed with a reverse phase column (Ultimate® XB-
C18 column 4.5 × 250 mm, 5µm) with the following solvent system: water/0.1% TFA (solvent A), 
acetonitrile (solvent B); 0–30 min: 25% B (system 1) or 0-30 min: 75% B (system 2). The flow rate 
was 1 mL/min and UV detection at 254 nm. Preparative HPLC was performed with a reverse phase 
preparative column (Ultimate® XB-C18 column 21.2 × 150 mm, 5µm) using the above mentioned 
isocratic conditions for analytical HPLC at a flow of 20 mL/min and UV detection at 254 nm. 
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Purification and analytics of the radiolabeled material was performed on a Merck Hitachi D-6000 
system equipped with multi-UV-wavelength and Raytest Gabi Star detectors and HSM software. A 
reverse phase column was used (LUNA® Phenomenex C18 5µm 4.5 x 250 mm) with the following 
solvent system: water/0.1% TFA (solvent A), acetonitrile (solvent B); flow 1 mL/min; 0 – 13 min: 
30% B, 13 – 18 min: 30 – 80% B, 18 – 36 min: 80% B, 36 – 38 min: 80 – 30% B, 38 – 40 min: 30% 
B; UV = 254 nm.  
4.5 Chemistry 
Ethyl 2-(4-iodobenzamido)acetate (1) 
 
To a solution of 4-iodobenzoic acid (1.5 g, 6.05 mmol) and N,N-diisopropyl-ethylamine (2.1 mL, 
12.1 mmol) in DMF (23.6 mL), O-(Benzotriazol-1-y)-N,N,N’,N’-tetra-methyluronium 
hexafluorophosphate (2.75 g, 7.26 mmol) was added portionwise at room temperature. After stirring 
for 15 min, a solution of glycin ethyl ester hydrochloride (0.748 g, 7.26 mmol) and N,N-
diisopropylethylamine (2.1 mL, 12.1 mmol) in DMF (10 mL) was added dropwise and the reaction 
mixture was stirred for 3 hours. The mixture was then diluted with ethylacetate and washed 
successively with 0.5 M HCl, 5% NaHCO3, H2O and brine. The organic layer was dried over MgSO4 
and concentrated in vacuo. After evaporating, the residue was purified by flash column 
chromatography on silica gel (hexane/AcOEt 7:3) to afford compound (1) (1.59 g, 79%) as light 
yellow solid. NMR data were in accordance with previously published data [37]. 
 
Rf : 0.24 (hexane/AcOEt 7:3). 1H-NMR (400 Hz, CDCl3): δ = 7.82 - 7.77 (m, 2H), 7.56 - 7.50 (m, 
2H), 6.68 (br, 1H), 4.26 (q, J = 7.2 Hz, 2H), 4.21 (d, J = 4.9 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H). 
 
2-(4-Iodobenzamido)acetic acid (2) 
 
To a solution of ethyl 2-(4-iodobenzamido)acetate (1.4 g, 4.2 mmol) in MeOH (35 mL) and H2O 
(35 mL), KOH (707 mg, 12.61 mmol) was added with continuous stirring and was kept for 1 h at room 
temperature, at which point TLC confirmed the complete consumption of the starting material (1). The 
reaction was then diluted with H2O (42 mL) and the pH of the solution was adjusted to 2 with HCl 1 
M. The precipitate was filtered off and washed with cold H2O. The compound was dried with a high 
vacuum pump (HVP) for 3 h to afford (2) (707 mg, 55%). 
 
Rf : 0.48 (DCM/MeOH/AcOH 9:1:0.02). 1H-NMR (400 Hz, DMSO): δ = 8.88 (t, J = 5.6 Hz, 1H), 
7.89 - 7.85 (m, 2H), 7.67 - 7.62 (m, 2H), 3.89 (d, J = 5.6 Hz, 2H). 13C-NMR (100 Hz, DMSO): δ = 
171.2, 165.7, 137.2, 133.3, 129.2, 99.1, 41.3. 
 
4-iodo-N-(2-oxo-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]-
dioxaborol-2-yl)pyrrolidin-1-yl)ethyl)benzamide (3) 
 
To an ice-cooled solution of 2-(4-iodobenzamido)acetic acid (300 mg, 0.983 mmol) in DCM (5.6 
mL), hydroxybenzotriazole (151 mg, 0.983 mmol) was added followed by EDC (245 mg, 1.278 mmol) 
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and the resulting mixture was stirred at room temperature for 30 min. N-Methylmorpholine (0.2 mL, 
1.967 mmol) and (R)-boroPro-(+)-pinanediol-HCl (245 mg, 0.983 mmol) were then added and stirring 
was continued for 16 h. The reaction mixture was diluted with DCM, washed successively with 1 M 
KHSO4, 10% Na2CO3, H2O and brine. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. After evaporating, the residue was purified by passing quickly through a short 
plug of silica gel, eluting with AcOEt, to afford compound (3) (489 mg, 93%). 
 
Rf : 0.52 (hexane/AcOEt 3:7). 1H-NMR (400 Hz, CDCl3): δ = 7.82 - 7.77 (m, 2H), 7.59 - 7.53 (m, 
2H), 6.65 (br, 1H), 4.33 (br, 1H), 4.15 (d, J = 3.8 Hz, 2H), 3.51 - 3.41 (m, 2H), 3.24 - 3.17 (m, 1H), 
2.39 - 2.30 (m, 1H), 2.22 - 1.96 (m, 5H), 1.94 - 1.78 (m, 4H), 1,46 (s, 3H), 1.29 (br, 3H), 0.84 (s, 3H). 
13C-NMR (100 Hz, CDCl3): δ = 166.5, 166.1, 137.9, 133.7, 128.9, 128.5, 98.8, 86.4, 78.1, 51.5, 45.9, 
42.5, 39.7, 38.5, 35.7, 28.7, 27.6, 27.3, 27.2, 26.5, 24.3. ESI-QTOF MS (DCM/MeOH) m/z calculated 
for C23H31BIN2O4 [M+H]+ 537.1420, measured 537.1414. 
 
(R)-(1-((4-iodobenzoyl)glycyl)pyrrolidin-2-yl)boronic acid (4) 
 
To a stirred solution of 3 (150 mg, 0.28 mmol) in acetone (7.4 mL) was added 0.1 M NH4OAc (6 
mL, 0.60 mmol) and NaIO4 (189 mg, 0.884 mmol). The mixture was stirred at room temperature for 
17 h, the acetone was removed in vacuo and the aqueous phase was turned basic with 2 M NaOH (9 
mL), washed with DCM and acidified cautiously to pH 2 with 2M HCl. The acidic solution was 
extracted with DCM (4x), dried over MgSO4, filtered and evaporated to dryness. The crude was 
purified with preparative HPLC using system 1 to afford compound 4 (45 mg, 45%). 
 
Rf : 0.19 (AcOEt). 1H-NMR (400 Hz, MeOD): δ = 7.88 - 7.83 (m, 2H), 7.65 - 7.59 (m, 2H), 4.42 - 
4.08 (m, 2H), 3.69 - 3.48 (m, 2H), 3.15 - 3.07 (m, 1H), 2.22 - 1.86 (m, 4H), 1.76 - 1.63 (m, 2H). 13C-
NMR (100 Hz, MeOD): δ = 139.1, 130.3, 129.5, 47.0, 46.8, 43.1, 41.9, 36.5, 28.8, 27.6, 21.9. HRMS 
C14H17BIN2O3 [M+H+-H2O+CH2] 399.0377, measured 399.0365. 
 
2-(4-(trimethylstannyl)benzamido)acetic acid (5) 
 
To a solution of 2-(4-iodobenzamido)acetic acid (331 mg, 1.085 mmol) in dry dioxane (6.7 mL), 
hexamethylditin (0.4 mL, 1.929 mmol) was added, followed by Pd(PPh3)2Cl2 (43.5 mg, 0.062 mmol) 
and the reaction mixture was heated under reflux for 3 h. After this time, the mixture was filtered 
through a pad Celite and the solvent was removed under reduced pressure. The crude was purified by 
flash column chromatography on silica gel (hexane/AcOEt/AcOH 60:40:0.4) to afford 5 (301 mg, 
81%) as a clear colorless oil [18]. 
 
Rf : 0.21 (hexane/AcOEt/AcOH 60:40:0.4). 1H-NMR (400 Hz, MeOD): δ = 7.81 - 7.77 (m, 2H), 
7.61 - 7.57 (m, 2H), 4.01 (s, 2H), 0.37 - 0.21 (br, 9H). 13C-NMR (100 Hz, MeOD): δ = 172.4, 170.1, 
148.5, 136.5, 134.6, 127.2, 43.0, - 2.2. MALDI MS (3-HPA) m/z calculated for C12H18NO3Sn [M+H]+ 
344.0305, measured 344.0304. 
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N-(2-oxo-2-((R)-2-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxabo-
rol-2-yl)pyrrolidin-1-yl)ethyl)-4-(trimethylstannyl)benzamide (6) 
 
To an ice-cooled solution of 2-(4-(trimethylstannyl)benzamido)acetic acid (220 mg, 0.643 mmol) in 
DCM (3.7 mL), hydroxybenzotriazole (99 mg, 0.643 mmol) was added followed by EDC (160 mg, 
836 mmol) with continous stirring and was kept for 30 min at room temperature. N-Methylmorpholine 
(0.15 mL, 1.287 mmol) and (R)-boroPro-(+)-pinanediol-HCl (160 mg, 0.643 mmol) were then added 
and the reaction mixture was stirred for 16 h. The reaction mixture was diluted with DCM and washed 
with 1 M KHSO4, 10% Na2CO3, H2O and brine. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The crude was purified with preparative HPLC using system 2 to afford 
compound (6) (216 mg, 59%) as a white solid. 
 
Rf : 0.56 (AcOEt). 1H-NMR (400 Hz, CDCl3): δ = 7.80 - 7.76 (m, 2H), 7.58 - 7.54 (m, 2H),6.64 (br, 
1H), 4.33 (br, 1H), 4.18 (d, J = 3.5 Hz, 2H), 3.54 - 3.41 (m, 2H), 3.24 - 3.18 (m, 1H), 2.37 - 2.29 (m, 
1H), 2.22 - 2.08 (m, 5H), 1.94 - 1.77 (m, 4H), 1,46 (s, 3H), 1.29 (s, 3H), 0.85 (s, 3H), 0.39 - 0.23 (s, 
9H). 13C-NMR (100 Hz, CDCl3): δ =167.5, 166.4, 136.2, 132.3, 128.6, 126.5, 98.7, 86.4, 78.1, 51.5, 
45.9, 42.5, 39.8, 38.5, 35.7, 28.6, 27.6, 27.4, 27.2, 26.5, 24.3, -9.3. ESI-QTOF MS m/z calculated for 
C26H40BN2O4Sn [M+H]+ 575.2106, measured 575.2102. 
4.6 Radiochemistry 
MeCN (500 µL), 50% H2SO4 (50 µL) and freshly prepared oxidant (100 µL, 4% CH3COOH and 
6.7% H2O2) were added to a sealed reaction vial. Na[125I] (1.3 - 34.6 MBq, Perkin Elmer, Waltham, 
USA) was diluted with water (ad 50 µL) and added simultaneously with the precursor (100 µL, 1 
mg/mL in MeCN) to the reaction mixture. The mixture was incubated for 10 min at room temperature 
with intermittent shaking. After this time, the reaction was quenched by the addition of 0.1 M Na2S2O3 
(200 µL). The product was purified by analytical RP-HPLC. Product identification was confirmed by 
co-injection of the reference 4. Radiochemical purity was determined by analytical HPLC.  
4.7 In vitro autoradiography 
For in vitro autoradiography, cryosections and paraffin-embedded sections of human atherosclerotic 
plaques (20 µm and 5 µm, respectively) and paraffin-embedded sections (5 µm) of a FAP-positive 
melanoma xenograft (human skin melanoma cell line Sk-Mel-187) and a FAP-negative xenograft 
(human lung small cell carcinoma cell line NCI-H69) were used. A Sk-Mel-187 xenograft was kindly 
provided by Dr. E. Fischer (Paul Scherrer Institut, Villigen, Switzerland). Cryosections were thawed 
and dried at room temperature for 30 min and all sections were subsequently incubated in HEPES 
buffer (50 mM HEPES, 5 mM MgCl2, 125 mM CaCl2, 0.1% BSA, pH 7.4) for 15 min on ice. The 
slices were incubated with [125I]MIP-1232 solution (2.95 nM in HEPES buffer, 0.1% BSA) or for 
blockade conditions with [125I]MIP-1232 solution containing additionally 100 µM unlabeled MIP-1232 
for 60 min at room temperature in a humidified chamber. After incubation, the slices were washed in 
HEPES buffer supplemented with 0.1% BSA (5 min), three times in HEPES buffer (3 min each) and 
distilled water (1 min) on ice.  For quantification of the radiotracer signal a calibration curve of a serial 
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dilution of the tracer solution on Whatman filter paper (Whatman, Bottmingen, Switzerland) was used. 
Dried slides and the filter papers were exposed to a BAS-MS 2025 phosphor imaging plate (Fuji Film, 
Dielsdorf, Switzerland) for 19 h. The plate was scanned in a BAS-5000 bio-imaging analyzer (Fuji 
Film, Dielsdorf, Switzerland). Data analysis and quantification was performed with the AIDA 4.5 
software (Raytest, Sprockhövel, Germany). Background values were subtracted from sample values 
and it was assured that all samples were within the linear range of the calibration curve. The integrated 
signal intensities were divided by the plaque size to correct for heterogeneity in tissue size. Specific 
binding was calculated by subtraction of the radioactivity signal under blockade conditions from the 
baseline signal.  
4.8 Statistical analysis 
Differences in mean values were evaluated by an unpaired two-tailed student’s t-test (Graph Pad 
Prism 6.0 software). A p-value <0.05 was considered significant.  
 
5. Conclusions  
Target expression analysis by IHC revealed moderately higher levels of FAP in plaques than normal 
arteries. The radiolabeled boronic acid-based inhibitor, [125I]MIP-1232, was successfully produced. 
The radiotracer displayed a specific binding to FAP-positive xenografts in vitro and accumulation in 
human carotid plaques in vitro. However, specific binding was similar in plaques and normal arteries 
and was independent of plaque vulnerability. Targeting FAP by [125I]MIP-1232 may, therefore, be of 
low relevance for atherosclerosis imaging but deserves further evaluation in tumor imaging. 
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